JP2023554674A5 - - Google Patents
Info
- Publication number
- JP2023554674A5 JP2023554674A5 JP2023537498A JP2023537498A JP2023554674A5 JP 2023554674 A5 JP2023554674 A5 JP 2023554674A5 JP 2023537498 A JP2023537498 A JP 2023537498A JP 2023537498 A JP2023537498 A JP 2023537498A JP 2023554674 A5 JP2023554674 A5 JP 2023554674A5
- Authority
- JP
- Japan
- Prior art keywords
- labeled protein
- sequence
- seq
- amino acid
- constant domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129480P | 2020-12-22 | 2020-12-22 | |
| US63/129,480 | 2020-12-22 | ||
| US202163170196P | 2021-04-02 | 2021-04-02 | |
| US63/170,196 | 2021-04-02 | ||
| PCT/US2021/073057 WO2022140774A1 (en) | 2020-12-22 | 2021-12-21 | Peptide markers to track genetically engineered cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554674A JP2023554674A (ja) | 2023-12-28 |
| JP2023554674A5 true JP2023554674A5 (https=) | 2024-12-20 |
Family
ID=80218522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537498A Pending JP2023554674A (ja) | 2020-12-22 | 2021-12-21 | 遺伝子改変細胞追跡用ペプチドマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220195006A1 (https=) |
| EP (1) | EP4267606A1 (https=) |
| JP (1) | JP2023554674A (https=) |
| KR (1) | KR20230124983A (https=) |
| AU (1) | AU2021410077A1 (https=) |
| CA (1) | CA3202874A1 (https=) |
| IL (1) | IL303809A (https=) |
| MX (1) | MX2023007445A (https=) |
| TW (1) | TW202241937A (https=) |
| WO (1) | WO2022140774A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021320556A1 (en) | 2020-08-07 | 2023-03-09 | Neogene Therapeutics B.V. | Methods to enrich genetically engineered T cells |
| WO2025219541A1 (en) * | 2024-04-19 | 2025-10-23 | Medigene Immunotherapies Gmbh | Constant uni-tabs |
| EP4635976A1 (en) * | 2024-04-19 | 2025-10-22 | Medigene Immunotherapies GmbH | Constant uni-tabs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1878744A1 (en) * | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
| WO2016079333A1 (en) * | 2014-11-20 | 2016-05-26 | Umc Utrecht Holding B.V. | Use of antibodies for enrichment of engineered t cells with exogenous immune receptors and antibodies for use in depletion of engineered t cells |
| EP3548055A4 (en) * | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| AU2018345400B2 (en) * | 2017-10-05 | 2024-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| WO2020201527A1 (en) * | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
-
2021
- 2021-12-21 US US17/557,514 patent/US20220195006A1/en active Pending
- 2021-12-21 KR KR1020237024600A patent/KR20230124983A/ko active Pending
- 2021-12-21 WO PCT/US2021/073057 patent/WO2022140774A1/en not_active Ceased
- 2021-12-21 EP EP21854791.7A patent/EP4267606A1/en active Pending
- 2021-12-21 MX MX2023007445A patent/MX2023007445A/es unknown
- 2021-12-21 IL IL303809A patent/IL303809A/en unknown
- 2021-12-21 JP JP2023537498A patent/JP2023554674A/ja active Pending
- 2021-12-21 TW TW110147984A patent/TW202241937A/zh unknown
- 2021-12-21 CA CA3202874A patent/CA3202874A1/en active Pending
- 2021-12-21 AU AU2021410077A patent/AU2021410077A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023554674A5 (https=) | ||
| Zhu | T helper cell differentiation, heterogeneity, and plasticity | |
| Obar et al. | Pathogen-induced inflammatory environment controls effector and memory CD8+ T cell differentiation | |
| Parronchi et al. | Effects of interferon‐α on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen‐specific T cells | |
| Panzer et al. | Rapid in vivo conversion of effector T cells into Th2 cells during helminth infection | |
| Nanjappa et al. | Effects of IL-7 on memory CD8+ T cell homeostasis are influenced by the timing of therapy in mice | |
| Sun et al. | NK cells and immune “memory” | |
| Annunziato et al. | Heterogeneity of human effector CD4+ T cells | |
| Flowers et al. | A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease | |
| Lin et al. | Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis | |
| Gallagher et al. | Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses | |
| Dikopoulos et al. | Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells | |
| Wakao et al. | Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation | |
| Stock et al. | Induction of T helper type 1–like regulatory cells that express Foxp3 and protect against airway hyper-reactivity | |
| Legge et al. | Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis | |
| Agnello et al. | Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights | |
| Cox et al. | Cytokines and the inception of CD8 T cell responses | |
| Spinner et al. | Transcriptional regulation of adaptive and innate lymphoid lineage specification | |
| Huang et al. | Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35 | |
| JP2024041873A5 (https=) | ||
| Chang et al. | Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals | |
| Ha et al. | IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization | |
| JP2016025858A5 (https=) | ||
| Tanaka et al. | Natural occurring IL-17 producing T cells regulate the initial phase of neutrophil mediated airway responses | |
| KR20000010799A (ko) | 억제인자 세포 집단을 생성시키기 위한 인터루킨-10의 용도 |